Return to: Pediatrics : Medical School : Academic Health Center : myU : U of M Home

Gold University of Minnesota M. Skip to main content. Link to University of Minnesota homepage
Pediatrics Blood and Marrow Transplantation
Whats Inside
For Patients and Families

Research

Education

Faculty and Staff

News & Events

Contact Us

 

Peds BMT Home




University Pediatrics Foundation - Make a Gift

Viking Children's Fund

Children's Cancer Research Fund

Home > Department of Pediatrics > Blood and Marrow Transplantation > News & Events > University of Minnesota Doctors Uncover Treatment for Advanced ALD Patients

Printer-friendly version   Mail this page to a friend

University of Minnesota Doctors Uncover Treatment for Advanced ALD Patients


MPLS/ST.PAUL (February 13, 2007) - Continuing with more than a decade of research, doctors at the University of Minnesota have discovered a treatment to help patients with advanced cases of adrenoleukodystrophy (ALD), a rare disorder affecting the nerves. The results are published in the late February issue of Bone Marrow Transplantation.

ALD is a progressive degenerative myelin disorder that affects young boys. Myelin is the "insulation" around the nerves and with ALD it breaks down over time and causes loss of hearing, sight, mobility, and general nerve function.

Left untreated, patients with ALD will die, usually within three to five years of diagnosis. There is no cure, but the progression of the disease can be halted with a bone marrow transplant. However, in very advanced cases, transplant is not recommended because patients die within a year despite the transplantation.

Doctors began giving patients with very advanced ALD who would not otherwise be eligible for transplant, a medication called N-acetyl L-cysteine (NAC), an anti-inflammatory drug used to help liver cells recover from Tylenol® (acetaminophen) overdose. In these advanced cases, the combination of NAC and transplant halted the disease progression and allowed these patients to survive a transplant. Post transplant brain scans showed a decrease in inflammation and preservation of myelin after administering NAC.

"We believe that NAC can also help patients with less advanced cases of ALD, and possibly other diseases of inflammation of the myelin," said Lawrence Charnas, M.D., Ph.D., senior author and pediatric neurologist at the University of Minnesota Children's Hospital. "This is a major step forward in treating a devastating disease."

The University of Minnesota Children's Hospital is among the world's leaders in treating children with ALD and other metabolic storage diseases. This research was funded by the Children's Cancer Research Fund and the University of Minnesota Department of Pediatrics.

The Academic Health Center is home to the University of Minnesota's six health professional schools and colleges as well as several health-related centers and institutes. Founded in 1851, the University is one of the oldest and largest land grant institutions in the country. The AHC prepares the new health professionals who improve the health of communities, discover and deliver new treatments and cures, and strengthen the health economy.


   


Feedback | Notice of Privacy Practices


 
The University of Minnesota is an equal opportunity educator and employer.